Effectiveness and Tolerability of Eptinezumab

Summary

The purpose of this prospective and multicentric study is to evaluate the effectiveness and tolerability of eptinezumab as preventive migraine treatment in a cohort of episodic or chronic migraine patients.

Conditions

• Migraine
• Migraine With Aura
• Migraine Without Aura
• Chronic Migraine

Interventions

DRUG

Eptinezumab 100 or 300 mg ev

Patients administered eptinezumab 100 or 300 mg ev quarterly for migraine prevention

Sponsors & Collaborators

• Azienda Ospedaliero Universitaria Policlinico Modena

  collaborator OTHER

• Società Italiana per lo Studio delle Cefalee

  collaborator OTHER

• IRCCS National Neurological Institute "C. Mondino" Foundation

  collaborator OTHER

• Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari

  collaborator OTHER

• Università degli Studi dell'Aquila

  collaborator OTHER

• University of Roma La Sapienza

  collaborator OTHER

• Euganea Health Unit, Padua, Italy

  collaborator UNKNOWN

• Azienda Ospedaliero-Universitaria di Parma

  collaborator OTHER

• Azienda Ospedaliera S. Maria della Misericordia

  collaborator OTHER

• A.O.U. Città della Salute e della Scienza

  collaborator OTHER

• Cliniche Humanitas Gavazzeni

  collaborator OTHER

• University of Campania Luigi Vanvitelli

  collaborator OTHER

• Ospedale Santo Stefano

  collaborator OTHER

• Azienda Policlinico Umberto I

  collaborator OTHER

• Auxologico San Luca

  collaborator OTHER

• Asst Degli Spedali Civili Di Brescia

  collaborator OTHER

• Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta

  collaborator OTHER

• University of Florence

  lead OTHER

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2024-03-26

Primary Completion

2025-04-30

Completion

2026-04-30

Countries

• Italy

Study Locations